Intellipharmaceuticals International Inc.
IPCI
IPCI was delisted on the 20th of March, 2019.
19 hedge funds and large institutions have $2.71M invested in Intellipharmaceuticals International Inc. in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 5 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
13% more capital invested
Capital invested by funds: $2.4M → $2.71M (+$308K)
14% less funds holding
Funds holding: 22 → 19 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
87% less call options, than puts
Call options by funds: $95K | Put options by funds: $737K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFA
First Foundation Advisors
Irvine,
California
|
+$434K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$341K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$237K |
| 4 |
ATC
Argent Trust Co
Nashville,
Tennessee
|
+$43.1K |
| 5 |
AG
Advisor Group
Phoenix,
Arizona
|
+$36.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$314K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$51K |
| 3 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$27K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$26K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$8.88K |
IPCI Hedge Fund Activity: Q2 2017 in Review
19 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Intellipharmaceuticals International Inc. (IPCI) for Q2 2017, worth a combined $2.71M — up 13% from $2.4M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of IPCI and 2 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 6 added.
The largest buyer was First Foundation Advisors, adding an estimated $434K. The largest seller was Deutsche Bank, cutting an estimated $314K.
- 19 institutional investors held Intellipharmaceuticals International Inc. (IPCI) as of Q2 2017, down from 22 in Q1 2017.
- Funds reported $2.71M of Intellipharmaceuticals International Inc. stock for Q2 2017, up 13% quarter-over-quarter.
- 2 funds opened new Intellipharmaceuticals International Inc. positions in Q2 2017 and 5 closed out, a net change of -3 holders.
- The largest Intellipharmaceuticals International Inc. buyer in Q2 2017 was First Foundation Advisors, an estimated $434K added.
- The largest Intellipharmaceuticals International Inc. seller in Q2 2017 was Deutsche Bank, an estimated $314K sold.
Based on aggregated 13F filings for Q2 2017.